DE3681466D1 - Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten. - Google Patents

Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.

Info

Publication number
DE3681466D1
DE3681466D1 DE8686300894T DE3681466T DE3681466D1 DE 3681466 D1 DE3681466 D1 DE 3681466D1 DE 8686300894 T DE8686300894 T DE 8686300894T DE 3681466 T DE3681466 T DE 3681466T DE 3681466 D1 DE3681466 D1 DE 3681466D1
Authority
DE
Germany
Prior art keywords
insulin receptor
production
antibodies
cleaning
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686300894T
Other languages
English (en)
Inventor
John Richard Bell
Axel Ulrich
Janakiraman Ramachandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE3681466D1 publication Critical patent/DE3681466D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE8686300894T 1985-02-12 1986-02-10 Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten. Expired - Lifetime DE3681466D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/700,776 US4761371A (en) 1985-02-12 1985-02-12 Insulin receptor

Publications (1)

Publication Number Publication Date
DE3681466D1 true DE3681466D1 (de) 1991-10-24

Family

ID=24814821

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686300894T Expired - Lifetime DE3681466D1 (de) 1985-02-12 1986-02-10 Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.

Country Status (6)

Country Link
US (1) US4761371A (de)
EP (1) EP0192392B1 (de)
JP (1) JPH074249B2 (de)
AT (1) ATE67504T1 (de)
CA (1) CA1341149C (de)
DE (1) DE3681466D1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5981481A (en) * 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
US5985587A (en) * 1984-08-17 1999-11-16 The Scripps Research Institute Polypeptide-induced monoclonal receptors to protein ligands
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
JPS63503309A (ja) * 1986-05-09 1988-12-02 カリフォルニア　バイオテクノロジー　インコーポレイテッド 心房性ナトリウム排出増加ペプチドレセプタータンパク
US6673896B1 (en) * 1986-08-21 2004-01-06 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
ATE135747T1 (de) 1986-08-21 1996-04-15 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US5688763A (en) * 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4962155A (en) * 1987-12-07 1990-10-09 City Of Hope Methods and compositions for activating the human insulin receptor kinase
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US6180368B1 (en) * 1988-03-23 2001-01-30 University Of Melbourne Ryegrass pollen allergen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
WO1989010939A1 (en) * 1988-05-13 1989-11-16 University Patents, Inc. Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
EP0378671B1 (de) * 1988-06-30 1997-03-12 City Of Hope Insulinomimetrische eigenschaften und insulin-rezeptor-bindestellen-peptide
US5227466A (en) * 1988-06-30 1993-07-13 City Of Hope Insulin receptor binding site
EP0364690A3 (de) 1988-08-23 1990-07-18 Dana Farber Cancer Institute Alpha-Subeinheit des Mac-1-Leukocyt-Adhäsions-Rezeptors
US6277591B1 (en) 1988-11-18 2001-08-21 Oregon Health Science University Dopamine receptors and genes
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
EP0452364B1 (de) * 1988-12-22 2002-05-22 Genentech, Inc. Verfahren zur herstellung von wasserlöslichen polypeptiden
US6261800B1 (en) 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
DE69015175T2 (de) * 1989-05-05 1995-06-29 Genentech Inc Glykoprotein-hormonrezeptor-moleküle.
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
DE69034061D1 (de) * 1989-07-18 2003-05-28 Osi Pharm Inc Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US6203976B1 (en) * 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5215963A (en) * 1989-10-24 1993-06-01 Berlex Laboratories, Inc. Solubilization and purification of the active gastrin releasing peptide receptor
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6265566B1 (en) 1990-08-17 2001-07-24 Immulogic Pharmaceuticals, Inc. Ryegrass pollen allergen
US5569601A (en) 1990-12-07 1996-10-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human dopamine receptor and its uses
WO1992013091A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
WO1992013063A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
RU2193599C2 (ru) 1991-03-15 2002-11-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Рецептор фолликулостимулирующего гормона (fsh) человека, днк, вектор, способ получения, фармацевтическая композиция
WO1993009141A1 (en) * 1991-11-01 1993-05-13 Joslin Diabetes Center Antigen associated with type i diabetes mellitus
US5532347A (en) * 1992-04-10 1996-07-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization DNA encoding α melanocyte stimulating hormone receptor
US5280112A (en) * 1992-04-10 1994-01-18 State Of Oregon, Oregon Health Sciences University DNA sequence encoding bovine and human adrenocorticotropic hormone receptors
AU1812595A (en) * 1994-02-28 1995-09-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
WO1995030775A1 (en) * 1994-05-06 1995-11-16 Nexstar Pharmaceuticals, Inc. High-affinity ligands of insulin receptor antibodies, tachykinin substance p, hiv integrase and hiv-1 reverse transcriptase
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
JP2002539833A (ja) 1999-03-31 2002-11-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル カリンレギュレーターｒｏｃ１およびｒｏｃ２をコードする単離ｄｎａ、それらによってコードされた単離タンパク質、ならびにそれらの利用法
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
AU4904800A (en) 1999-05-27 2000-12-18 Robert Z-T. Luo Identification of compounds for modulating dimeric receptors
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
CN102180944A (zh) 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
US7514593B2 (en) * 2003-05-30 2009-04-07 The University Of North Carolina At Chapel Hill Animal model for chronic obstructive pulmonary disease and cystic fibrosis
CN103356636A (zh) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein调节剂
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
EP4424838A2 (de) * 2005-11-23 2024-09-04 Gerard M. Housey Verbindungen und verfahren zur identifizierung, synthese, optimierung und profilerstellung von proteinmodulatoren
WO2007075976A2 (en) 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
EA200802440A1 (ru) * 2006-06-06 2009-06-30 Олег Ильич ЭПШТЕЙН Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
AU2008245524A1 (en) 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
US20150307863A1 (en) 2012-11-20 2015-10-29 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
WO2024014953A1 (en) 2022-07-12 2024-01-18 Resiliun B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5492691A (en) * 1977-12-27 1979-07-23 Mitsubishi Chem Ind Ltd Preparation of desoxyribonuclease
JPS566276A (en) * 1979-06-29 1981-01-22 Ricoh Co Ltd Developing device
JPS57146580A (en) * 1981-03-09 1982-09-10 Seikagaku Kogyo Co Ltd Separation and purification of enzyme in human urine
JPS6030512B2 (ja) * 1982-11-26 1985-07-17 科学技術庁長官官房会計課長 制限エンドヌクレア−ゼの調製法

Also Published As

Publication number Publication date
EP0192392B1 (de) 1991-09-18
ATE67504T1 (de) 1991-10-15
JPS61251700A (ja) 1986-11-08
JPH074249B2 (ja) 1995-01-25
EP0192392A3 (en) 1986-11-20
EP0192392A2 (de) 1986-08-27
US4761371A (en) 1988-08-02
CA1341149C (en) 2000-12-05

Similar Documents

Publication Publication Date Title
DE3681466D1 (de) Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.
Gray et al. Expression of human immune interferon cDNA in E. coli and monkey cells
DE69026627T2 (de) Antikörperantagonisten gegen humanes interleukin-4
DE68923401T2 (de) Peptide mit T-Zellen-Helfer-Wirksamkeit.
DE69518156T2 (de) Immunomodulatoren
DE3854952T2 (de) Mykobakterielle rekombinanten und peptide
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3588095D1 (de) Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung
ATE74513T1 (de) Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen.
CH634039A5 (de) Somatostatinanalogon, sowie verfahren zu seiner herstellung.
NZ337955A (en) Modified TNF-alpha and their use as vaccines
DE68914205T2 (de) Zyklische GRF-Analoge.
ATE6251T1 (de) Acylpeptide und pharmazeutische praeparate davon, sowie deren herstellung und verwendung.
PT79230B (en) Process for producing a homogeneous imune interferon fragment and of pharmaceutical compositions containing the same
DE69115917T2 (de) Humane gammainterferonantagonisten
JPH04503602A (ja) Ｉｌ―１生物活性の抑制剤
ATE38988T1 (de) Imidazolylphenyl-tetrahydropyridazine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
CN1054772A (zh) 合成多肽
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
DE69734723T2 (de) High-Affinity Interleukin-4 Muteins
FI902569A0 (fi) Producering av till gonorre anslutande pi-proteiner och vaccin.
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
DE69018702D1 (de) Verfahren zur Herstellung eines Antikaries-Impfstoffes aus Streptococcus mutans und Impfzusammensetzung gegen Karies in Form von Nasentropfen.
DE50301507D1 (de) 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
DE2718718A1 (de) Somatostatinanaloge und zwischenprodukte hierzu

Legal Events

Date Code Title Description
8364 No opposition during term of opposition